Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by Arbourmarkon Dec 07, 2021 2:01pm
109 Views
Post# 34207254

RE:RE:Market Manipulation Continues

RE:RE:Market Manipulation Continues

They will continue to do this for a number of reasons. There are no buyers because we have no Analyst coverage, we are lucky to trade 10,000 shares a day on US listing.

I will point out that house 22 is the market maker and if that house was not buying this would go much lower.

This is sad to watch day in and day out. This is exactly what these short sellers want to do, manufacture fear, get weak retail hands  to throw in the towel and sell into weakness to drive it lower so they can accumulate some volume a lower prices.

The markets are rigged by the big boys.

The past 3 days have created lower highs and lowers lows, this will be below $4 in near future until it gets to a price where buyers come in.

I know it is hard stomach this blatant manipulation!
 



stocksarefun wrote: Couldn't have said it any better.

this market is ripe with manipulation, no way around that. Bigger exchanges will bring smarter manipulators. The real problem we have here is a lack of bids, and a lack of demand. Hoping that the third party review is a US Entity that will provide US exposure, because that's where the money and biotech demand is from institutions.

The Press release, while it exceeded my expectations, failed to disclose anything about US participation, funding, investment, or acknowledgement. That, in my opinion, is the ticket to liftoff.

 

<< Previous
Bullboard Posts
Next >>